{filename}

Publications

Categories

Filter by Topics

478P TA-ness ADCC Gene Alteration adolescents ALK Angiogenesis Anti-TNF Alpha Therapy antiEGFR apoptosis Apoptosis Asthma Autocrine Signaling Autoimmune Disorder B Cells benign Biofluid Biology of neoplasia Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Blood Brain Breast Cancer Breast milk cancer genetics Cancer Genomics Cardiovascular Disease CD3 CDKN2A mutation Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor classifications cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA cyclic AMP‑dependent transcription factor ATF‑4 Cytokines Cytotoxic T Cells cytotoxicity Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy end stage kidney disease epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma GEIS Gene Expression gene expression gene expression profiling Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC IMMUNOSARC Immunotherapy Inflammation Integrins inverted papilloma ISG Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis Lymphocytes Lymphoma lymphomas machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma multiple myeloma Muscle mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic nivolumab non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway analysis Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PFAS PIK3CA mutation Placenta placenta Plasma Platform Comparison predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate prostate cancer Prostate Cancer prostate genomics Protein Protein Interaction network qNPA qPCR race disparities Radioimmunotherapy RAS Rearrangements Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium Squamous cell carcinoma squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer TMB tomentosin Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue Zanubrutinib

New tools for Biomarker Discovery Promise Personalized Treatment for Rheumatoid Arthritis

This webinar will outline an ongoing project to develop personalized treatment strategies for rheumatoid arthritis patients using miRNA profiling. 

Millions of patients with rheumatoid arthritis are treated with TNF-α inhibiting agents, but the response rate to these therapies is low (30 percent to 40 percent) and no tool exists to predict the treatment response.

In the study that will be discussed in this webinar, Dr. Eric Schordan, Head of the Molecular Diagnostic Department at Firalis and TcLand Expression, led a project that aimed to address this via miRNA profiling in RA patients.

Using the HTG EdgeSeq platform, Dr. Schordan and colleagues first identified sets of miRNAs that discriminate responders from non-responders to anti TNF-α therapy and then developed a panel called RABIOPRED that includes more than 2,100 mRNAs identified as predictors of anti TNF-α therapy.

In a study that enrolled 67 RA patients, Dr. Schordan and his team determined that miRNA profiling using the HTG EdgeSeq platform served as a useful tool for biomarker discovery and enabled them to build predictive models for response to anti-TNF-α drugs. 

In this webinar, Dr. Schordan will discuss the details of that study, as well as his team's plans to validate the panel in a multicentric prospective clinical study of 600 patients.

Speaker

Eric Schordan
Head of the Molecular Diagnostic Department at Firalis and TcLand Expression.

Speaker Biography

Eric received his PhD in molecular and cellular biology from University Louis Pasteur, Strasbourg, in 2005. After his PhD, he held a postdoctoral position at the University of Heidelberg with the support of an IEF Marie-Currie fellowship and a position of researcher at the University Medical Center Greifswald in the field of molecular and cellular biology. He was selected in 2007 for the participation to the 57th Meeting of Nobel Laureates in Lindau. In 2013 he joined Firalis to create the department of Molecular Diagnostics for the discovery, validation and qualification of nucleic biomarkers.

Return To List